@FiercePharma: India's Torrent completes deal to buy family-run Zyg Pharma, gets FDA plant. More from FiercePharmaAsia | Follow @FiercePharma
@CarlyHFierce: ICYMI: Bayer homes in on €10B plastics IPO with plans for summer roadshow. Report | Follow @CarlyHFierce
> Sanofi ($SNY) and Regeneron's ($REGN) cholesterol drug Praluent and GlaxoSmithKline's ($GSK) malaria vaccine could win backing from E.U. regulators as soon as this week. Report
> Novartis ($NVS) says its eye drug Lucentis is more cost-effective than Bayer's Eylea for treating diabetic macular edema, in an analysis published in ClinicoEconomics and Outcomes Research. Report
> Baxter ($BAX) pulled two lots of its saline solution after a customer complaints about insect particles in the IV bags. Report
> Sun Pharma said its merger with Ranbaxy Laboratories would take a toll on its revenue and profits, partly because of the costs of integrating the two companies and fixing problems at Ranbaxy facilities. Report
> European officials approved CSL's buyout of Novartis' flu vaccines business. Report
Medical Device News
@FierceMedDev: Alere revs up engine with new deals and win for quick strep test. FierceDiagnostics story | Follow @FierceMedDev
@VarunSaxena2: ICYMI: Indian stentmakers gaining global foothold--is U.S. market next? More | Follow @VarunSaxena2
@EmilyWFierce: Kim Kardashian speaks out for Duchesnay's morning sickness drug, Diclegis. FiercePharmaMarketing press release | Follow @EmilyWFierce
> Boston Scientific faces reimbursement hurdles for lung-searing asthma treatment. Story
> UCLA adopts startup cleaning system to help stop spread of superbugs via duodenoscopes. Article
Biotech News
@FierceBiotech: ICYMI yesterday: Tekmira changes its name and shuffles away from Ebola. News | Follow @FierceBiotech
@JohnCFierce: ICYMI: Adaptimmune touts a promising snapshot of TCRs for myeloma. More | Follow @JohnCFierce
@DamianFierce: You can watch The Atlantic's AAIC2015-adjacent chat thing, ft. $LLY, here. | Follow @DamianFierce
> Big Pharma pushes new migraine drugs into Phase III with blockbuster hopes. Item
> 'Cures' bill, designed to speed drug approvals, could be too much of a good thing, dissenters say. More
> Athyrium debuts a $1.2B fund to bet on biopharmas. Article
Drug Delivery News
> Two oral therapeutics specialists bag a combined $140M via IPO, VC funding. Item
> Glucose delivery pathway that feeds tumors could be exploited to knock them down. More
> Minimally invasive brain probe uses light flashes to target drugs. Story
> Purdue team developing smart capsule for diseases of the large intestine. Report
> Novo to sell shield for concealing the needle of its injection pens. Article
Pharma Manufacturing News
> Biogen gets all of North Carolina site from Eisai as part of manufacturing build-out. Story
> Amgen's Colorado plant hits the market for $85M. Item
> Valeant gets manufacturing in Middle East with deal for Amoun. More
> Baxter IDs particulate in recalled saline as insects. Article
> AMRI picks up Spanish drugmaker in $174M deal. News
Pharma Asia News
> AdvaMed welcomes legislation to separate India's device and drug oversight. Item
> ASLAN and Singapore's NCCS plan studies on Asia-prevalent cancers. More
> India's Sun Pharma sees multiyear earnings hit as it fixes plants, integrates Ranbaxy. Report
> Medidata's de Vries on disruption in Asia drug research with Japan a focus. Story
> Singapore's biopharma industry: Where the jobs are. Article
And Finally... People at high risk of contracting HIV took their preventive meds--pre-exposure prophylaxis, or PrEP--mostly as directed in a new study; despite FDA approval to stave off HIV infection, Gilead Sciences' ($GILD) Truvada hasn't been widely adopted for that use. Release